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underwent surgery between October 1999 and September 2000 were included in the intervention group. Overall, 421 patients underwent 448 elective primary total hip or knee replacement operations. However, 4 patients had an operation before and after the implementation of the flow chart. There were 208 patients (who underwent 224 unilateral and two bilateral operations) in the control group and 217 patients (who had 218 unilateral and four bilateral operations) in the intervention group. The mean age was 69.6 years in the control period and 71.0 years in the intervention period. The proportion of women was 50.5% in the control period versus 56.7% in the intervention period.
Study design
This was a comparative study with historical control, and was carried out at a single institution, namely the Kantonsspital Winterthur in Switzerland. The length of follow-up was not reported, but patients were presumably followed until hospital discharge. No patient was lost to follow-up. Blinding was not performed. The authors pointed out that all operative and perioperative procedures, including surgical techniques and types of implants, remained identical.
Analysis of effectiveness
All patients included in the initial study sample were taken into account in the analysis of effectiveness. The primary outcome measure was the proportion of patients receiving blood transfusions (allogenic, autologous, or both). Other outcomes were proportion of allogeneic transfusions that did not fulfil the criteria for red blood cell transfusions published by the American College of Physicians; number of blood units used; number of patients donating blood preoperatively; frequency of adverse events; and length of perioperative admission. Odds ratios (ORs) were calculated using a regression model to assess the likelihood of blood transfusions in the intervention period in comparison with the control period, adjusting for age, sex, presence of risk factors, preoperative haemoglobin concentrations, type of surgery, bilateral operation, type of anaesthesia, duration of operation, estimated intraoperative blood loss, and postoperative haemoglobin concentrations. At baseline, study groups were comparable, except for preoperative haemoglobin levels (which were higher in the intervention period) and duration of surgery (which was shorter in the control period).
Effectiveness results
The proportion of patients receiving blood transfusions decreased from 35.0% (79 operations) to 19.8% (44 operations) for allogeneic blood (difference: -15.2%; 95% confidence interval (CI): -23.3 --7.0%); from 28.8% (65 operations) to 5.9% (13 operations) for autologous blood (difference: -22.9%; 95% CI: -29.6 --16.2%); and from 59.7% (135 operations) to 24.8% (55 operations) for any blood transfusion (difference: -35.0%; 95% CI: -43.5 --26.4%).
The proportion of patients receiving allogeneic transfusions significantly decreased around November 1999, which was the month after the implementation of the flow chart.
The proportion of allogeneic transfusions that did not fulfil the criteria for red blood cell transfusions published by the American College of Physicians decreased from 43.8% to 15.9% (difference: -27.9%; 95% CI: -43.2 --12.5%).
The number of blood units used decreased from 200 to 102 for allogeneic blood (difference: -0.43 units per total joint replacement operation; 95% CI: -0.66 --0.19) and from 127 to 25 for autologous blood (difference: -0.45 units per operation; 95% CI: -0.59 --0.31).
The number of patients donating blood preoperatively fell from 98 patients (47.1%) donating 245 units during the control period to 53 patients (24.4%) donating 107 units during the intervention period.
The adjusted OR was 0.20 (95% CI: 0.10 -0.39) for allogenic transfusions, 0.14 (95% CI: 0.06 -0.33) for autologous transfusions, and 0.07 (95% CI: 0.03 -0.14) for any transfusion.
No serious adverse events were observed in either period. The length of perioperative admission was similar between the two groups.
The number of allogenic transfusions was also evaluated in Switzerland and in the region of Zurich, and no clear trend
CRD COMMENTARY -Selection of comparators
The selection of the comparator was appropriate as it reflected the standard treatment approach used before the introduction of the flow chart. You should decide whether this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness data were estimated by means of a comparison between a prospective group and a historical control group. This design was selected because the new intervention and the comparators were implemented in two different time periods. As the two groups of patients were not assessed concurrently, factors other than the study interventions might have affected the results of the analysis. However, the authors analysed the trend of the main outcome measure outside their institution over the period covered by the study, and no significant change was observed. Furthermore, it was pointed out that operative procedures at the study institution did not change over time. Thus, the study should have captured the true intervention effect. To further enhance the robustness of the analysis, a regression analysis was also used taking into account the impact of potential confounding factors. However, study groups were not perfectly matched at baseline, and the difference in haemoglobin levels could have resulted in a decrease in the perceived need for transfusions. A further limitation of the analysis was the fact that evidence came from a single institution, and may therefore not have been representative of the general population of patients considered in the study. However, consecutive patients were enrolled. Another issue that was highlighted by the authors was that patients were not followed after hospital discharge, thus some serious adverse events could have been missed. The size of the sample was defined on the basis of statistical tests and all patients initially included were taken into account. These issues should be considered when assessing the internal validity of the analysis.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-consequences analysis was conducted. Please refer to the commentary reported above under 'Validity of estimate of measure of effectiveness'.
Validity of estimate of costs
The categories of costs included in the analysis suggest that a hospital perspective may have been used, although this was not clearly stated. Extensive information on unit costs and quantities of resources used was provided, which will help with replicating the analysis in other settings. The source of data was not stated but is likely to have been the hospital's accounting system. Cost estimates were specific to the study setting and the impact of using alternative economic estimates was not investigated. The price year was not given, thus limiting the possibility of reflating the costs in different time periods. Statistical analyses of costs were not performed.
Other issues
Comparisons of the current findings with those from other studies were not made. Furthermore, the authors did not address the issue of the generalisability of their results to other settings. Since sensitivity analyses were not performed, the external validity of the study was limited. However, replicating the cost analysis should be possible as details of costs and resource use were extensively reported. The study referred to patients undergoing primary total hip and knee replacement and this was reflected in the authors' conclusions. Some limitations of the study were noted and have been reported in the fields above.
